Psoriasis and Ischemic Coronary Artery Disease

Mahiques-Santos, Laura; Soriano-Navarro, C.J.; Pérez‐Pastor, Gemma; Tomas-Cabedo, G.; Pitarch-Bort, Gerard; Valcuende‐Cavero, Francisca

doi:10.1016/j.adengl.2014.12.014

Cited by 10 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myocardial infarction (MI) may be the first manifestation of CAD, and its risk may be increased up to threefold, compared with non-psoriatic controls. [67][68][69] Interestingly, higher prevalence of psoriasis among CAD patients has also been reported. 70 Certain polymorphisms of the human gene IL-23 R have been associated with the risk and severity of atherosclerosis.…”

Section: Coronary Artery Diseasementioning

confidence: 97%

“…Coronary artery disease (CAD) has been showed to have higher prevalence among psoriasis patients. Myocardial infarction (MI) may be the first manifestation of CAD, and its risk may be increased up to threefold, compared with non‐psoriatic controls . Interestingly, higher prevalence of psoriasis among CAD patients has also been reported …”

Section: Psoriasis and Cardiovascular Diseases: What Is The Place Formentioning

confidence: 99%

See 1 more Smart Citation

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis

Egeberg

Gisondi

Carrascosa

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Alterations in the innate and adaptive immunity underpin psoriasis pathophysiology, with the Th17 cells subset now recognized as the fundamental cells in the key controlling pathway involved in its pathogenesis. Since psoriasis is a systemic disease with important comorbidity, further knowledge on the interleukin (IL)-23/Th17 axis led to the hypothesis that there may be shared pathogenic pathways between primary skin disease and comorbidity. Psoriasis has been identified as a risk factor for cardiovascular and metabolic disease, and increasing evidence gives support to this epidemiological observation from the clinical-pathologically field. As an example, increased levels of IL-23 and IL-23R have been found in human atherosclerotic plaque, and levels correlated with symptom duration and mortality. Also, upregulation of IL-23/IL-17 seems to play an important role in both myocardial damage and stroke, with interesting reports on deleterious effect neutralization after administration of related anti-bodies in both associated conditions. In diabetic patients, increased levels of IL-23/IL-17 have also been observed and available data support a synergistic role of IL-23/IL-17 in b-cells damage. In obesity, signs of an expansion of Th17 subset in adipose tissue have been reported, as well as elevated concentrations of IL-23 in obese patients. In non-alcoholic fatty liver disease, closely related to metabolic syndrome, but also in other mentioned cardiometabolic disorders, a predominance of IL-23 and other related proinflammatory factors has been identified as participating in their pathogenesis. Thus, the involvement of the IL-23/Th17 axis in these shared psoriasis-cardiometabolic pathogenic mechanisms is reviewed and discussed in the light of the existing preclinical and clinical evidence, including that from comorbid psoriasis patients.

show abstract

Section: Coronary Artery Diseasementioning

confidence: 97%

Section: Psoriasis and Cardiovascular Diseases: What Is The Place Formentioning

confidence: 99%

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis

Egeberg

Gisondi

Carrascosa

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Direct transcripts of the executed search strategies were listed in appendix data (Additional file 3, Additional file 4 and Additional file 5). A total of 9 CAD articles [3,6,[36][37][38][39][40][41][42], 9 MI articles [2,4,[43][44][45][46][47][48][49], and 6 HF articles [5,6,42,48,50,51] were ultimately enrolled in the three meta-analyses after screening, respectively. With regard to studies from Europe versus East Asia, there were, respectively, 6 versus 3 CAD studies, 5 versus 4 MI studies, and 5 versus 1 HF studies.…”

Section: Observed Associations Between Psoriasis and Cad MI And Hf Riskmentioning

confidence: 99%

Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis

Zhang

Wang

Qiu

et al. 2022

BMC Med

View full text Add to dashboard Cite

Background Psoriasis has been linked to cardiovascular disease (CVD), including coronary artery disease (CAD), myocardial infarction (MI), and heart failure (HF). However, available studies regarding this relationship have shown inconsistent results. Therefore, in this report, we performed a comprehensive review of the literature to assess the effects of psoriasis on risk of these CVDs. Methods A search of literature until 24 December 2021 was done in PubMed, the Cochrane Library, Web of Science, Google Scholar, and Embase. Within European and East Asian populations, meta-analyses of observational studies assessing correlations between psoriasis and various CVD risk factors were conducted. Mendelian randomization (MR) was then employed to assess the causative impact of genetic pre-disposition for psoriasis on these CVD risk factors. Results The results of the meta-analyses indicated that, in both the European and East Asian populations, psoriasis was significantly linked to an elevated risk in the incidence of CAD (RR = 1.51, 95% confidence interval (CI): 1.04–2.18, p = 0.028 and RR = 1.91, 95% CI: 1.62–2.25, p < 0.001) and MI (RR = 1.23, 95% CI: 1.04–1.46, p = 0.017 and RR = 2.17, 95% CI: 1.44–3.28, p < 0.001). A positive genetic relationship of psoriasis with CAD was found in European individuals (IVW OR:1.03; 95% CI: 1.01–1.06, p = 0.005) and in East Asian individuals (IVW OR:1.18; 95% CI: 1.03–1.32, p = 0.031). We also established that psoriasis was causally linked with an elevated risk of MI (IVW OR:1.05; 95% CI: 1.01–1.09, p = 0.026) in the European population as determined using an MR approach. Moreover, our MR results were congruent with the null findings from the meta-analysis assessing associations of psoriasis with HF risk. Conclusions This research work provides preliminary evidence that psoriasis and CVD have a common genetic origin and that targeted psoriasis treatment might improve cardiovascular outcomes. These results not only increase our knowledge of the genetic underpinnings linking a comorbidity of psoriasis with CVD but also suggests a novel approach for CVD prevention.

show abstract

“…Although classified as skin disease, psoriasis is associated with systemic inflammatory conditions that include obesity, diabetes, and cardiovascular disease (Kimball et al, 2008). Patients with psoriasis have an increased risk of myocardial infarction and stroke, and psoriasis is now recognized as an independent risk factor for coronary heart disease and cardiovascular mortality (Ahlehoff et al, 2012;Armstrong et al, 2012Armstrong et al, , 2013Dregan et al, 2014;Gelfand et al, 2006;Kaye et al, 2008;Ludwig et al, 2007;Mahiques-Santos et al, 2015;Mehta et al, 2010;Shiba et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment

Kim

Tomalin

Lee

et al. 2018

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Patients with psoriasis have an increased risk of myocardial infarction, and psoriasis is now recognized as an independent risk factor for coronary heart disease and cardiovascular mortality. To understand the effects of psoriasis medications on systemic inflammation associated with cardiovascular risks, we studied blood proteins related to inflammation and cardiovascular disease archived from a phase 3 clinical trial of tofacitinib and etanercept in adults with moderate-to-severe psoriasis. A total of 157 blood proteins were quantified by a proximity extension assay from 266 patients at baseline and week 4. Protein changes in the blood after 1 month of treatment were compared between tofacitinib (10 mg two times a day) and etanercept (50 mg biweekly), and by response status at week 12. Tofacitinib and etanercept commonly reduced IL-6, CCL20, and CXCL10, but IL-17A was significantly reduced only in responders of either treatment. Compared with etanercept, tofacitinib showed a wider spectrum of cardiovascular blood protein reduction, but the protein reduction effects of tofacitinib were strictly confined to treatment responders. Tumor necrosis factor receptor 1, E-selectin, hK11, tumor necrosis factor-related activation-induced cytokine, CHI3L1, IL-16, and matrix metalloproteinase-12 were cardiovascular proteins significantly reduced only in tofacitinib responders. Our data suggest that a short-term systemic psoriasis treatment can cause reductions in circulating inflammatory and other proteins associated with cardiovascular risks.

show abstract

Psoriasis and Ischemic Coronary Artery Disease

Abstract: Our findings in a large sample of patients in a Mediterranean area support the hypothesis that patients in this population have an increased risk of ischemic CAD.

Cited by 10 publications

References 17 publications

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis

Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis

Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment

Contact Info

Product

Resources

About